About Bluebird Ventures
Bluebird Ventures is a venture capital firm founded in 2019. It is primarily based out of Palo Alto, United States. As of Jul 2024, Bluebird Ventures has invested in 8 companies. It primarily invests in Series B round in United States based startups. Its investments are spread across Life Sciences and High Tech sectors. Most recently it participated in the $***** Series B round of Foresight Diagnostics Overall, Bluebird Ventures portfolio has seen 2 acquisitions, namely Foresight Diagnostics and Forty Seven. A lot of funds co-invest with Bluebird Ventures, with names like Civilization Ventures sharing a substantial percentage of its portfolio.Key Metrics
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 1 more
Portfolio Acquisitions
Portfolio Soonicorns
Bluebird Ventures' List of Top Investments
Bluebird Ventures has a portfolio of 8 companies. Their most notable investments are in Foresight Diagnostics and Foresight Diagnostics.Their portfolio spans across United States and Netherlands. They have invested in Life Sciences, High Tech, across Series A, Series B and 1 more. Here is the list of top investments by Bluebird Ventures:
Developer of minimally-invasive liquid biopsy test for the detection of cancer. The company uses PhasED-Seq technology to develop liquid biopsy testing platform enabling detection of ctDNA levels in patients with solid tumors and hematologic malignancies.
Key facts about Foresight Diagnostics
- Founded Year: 2020
- Location: Aurora (United States)
- Stage: Acquired
- Total Funding till date: $104M
- Employee Count: 112 as on Aug 31, 2026
- Investors: Foresite Capital, Fidelis Ventures and 6 Others
- Latest Funding Round: Series B, Jul 30, 2024, $*****
- Highlight: Acquired
Developer of therapeutic solutions for the treatment of diabetes. The company has developed AAV-based gene therapies for the treatment of type 1 and type 2 diabetes. Its drug candidate KT-A112 contains insulin and glucokinase proteins that help in treating Type 1 & Type 2 diabetes mellitus. It also provides KT-A522 with glucagon-like peptide (GLP-1) receptor agonist for the treatment of Type 2 diabetes, KT-A832 insulin growth factor that helps in treating diabetes mellitus.
Key facts about Kriya Therapeutics
- Founded Year: 2012
- Location: Redwood City (United States)
- Valuation: $*****
- Stage: Series D
- Total Funding till date: $938M
- Employee Count: 10 - 49 as on Mar 01, 2026
- Investors: Foresite Capital, CAM Capital and 16 Others
- Latest Funding Round: Series D, Jul 31, 2025, $*****
- Highlight: Editors' Pick
3. Leyden Labs
Developer of nasal sprays containing antibodies targeting respiratory viruses in the nasal mucosa. It develops nasal sprays that stop initial infection, prevent onward transmission, protect broadly against existing and new viruses, and provide universal protection, regardless of an individual’s immune history or comorbidities. The company focuses on harnessing mucosal immunity and broad protection by delivering antibodies directly to the nasal mucosa for immediate anti-viral protection. It develops active substances that target regions that lend themselves to lasting protection against multiple strains and entire virus families.
Key facts about Leyden Labs
- Founded Year: 2020
- Location: Leiden (Netherlands)
- Stage: Series B
- Total Funding till date: $303M
- Employee Count: 81 as on Aug 31, 2026
- Investors: SoftBank Vision Fund, F-Prime Capital and 14 Others
- Latest Funding Round: Series B, Jun 25, 2026, $*****
- Highlight: Editors' Pick
4. Procyrion
Developer of percutaneous mechanical circulatory support devices for heart failure. This device functions by increasing aortic flow and renal perfusion to assist patients experiencing acute decompensated heart failure. The technology utilizes a pump to accelerate blood flow, aiming to reduce cardiac workload and address cardiorenal syndrome. The system is designed for percutaneous deployment to provide circulatory support in clinical settings.
Key facts about Procyrion
- Founded Year: 2005
- Location: Houston (United States)
- Stage: Series E
- Total Funding till date: $114M
- Employee Count: 32 as on Aug 31, 2026
- Investors: Scientific Health Development, Texas Ventures and 6 Others
- Latest Funding Round: Series E, Feb 05, 2024, $*****
- Highlight: Editors' Pick
_1578289648591.png?format=webp&height=120&width=120){kind=logo}
5. Epirium Bio
Epirium Bio is a developer of therapeutic solutions for the treatment of cancer patients. It is developing viral immunotherapies that promote mitochondrial biogenesis and function. The company is developing for cancer patients. The company has identified and established an IP-protected platform of small molecules that constitute a new class of therapeutics with the potential to stimulate mitochondrial biogenesis and function.
Key facts about Epirium Bio
- Founded Year: 2008
- Location: San Diego (United States)
- Stage: Series A
- Total Funding till date: $85M
- Employee Count: 13 as on Aug 31, 2026
- Investors: Adams Street Partners, Longitude Capital and 5 Others
- Latest Funding Round: Series A, Dec 18, 2019, $*****
- Highlight: Editors' Pick
Bluebird Ventures' Year-on-Year Investment Trends
Bluebird Ventures has invested in 8 companies over the last 7 years, with an average of 0 new investment annually in the last 5 years. Its most recent first time investment was in Leyden Labs and most recent follow-on round was in Foresight Diagnostics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 0 | 0 |
2024 | 0 | 2 | 2 |
2023 | 0 | 1 | 1 |
2022 | 1 | 1 | 2 |
2021 | 2 | 0 | 2 |
2020 | 0 | 0 | 0 |
2019 | 2 | 0 | 2 |
Bluebird Ventures' Investments by Stage
Bluebird Ventures has made 2 investments in Series A stage with an average round size of $48.8M, 2 investments in Series B stage with an average round size of $120M and 1 investment in Series D stage with an average round size of $30M.Stage of entry | No. of Investments |
|---|---|
Series A | 2 |
Series B | 2 |
Series D | 1 |
Note: We have considered here, only first round of investments
Bluebird Ventures' Investments by Sector
Bluebird Ventures has a diverse portfolio, with companies operating in the Life Sciences, High Tech and Sustainability Tech. Notably, it has invested in 8 Tech companies, 7 Enterprise (B2B) companies, 2 Software companies and at least 2 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 5 |
High Tech | 2 |
Sustainability Tech | 1 |
Note: We have considered here, only first round of investments
Bluebird Ventures' Investments by Geography
Bluebird Ventures has made most investments in United States (4), followed by Netherlands where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 4 |
Netherlands | 1 |
Note: We have considered here, only first round of investments
Bluebird Ventures' recent investments
Bluebird Ventures has not made any investment in 2026 so far.Here are the most recent investments by Bluebird Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jul 30, 2024 | United States | Series B | 3999 | [+5] | |
Feb 05, 2024 | United States | Series E | 3243 | ||
Apr 27, 2023 | United States | Series B | 3289 | [+4] | |
May 10, 2022 | United States | Series C | 4931 | ||
Jan 25, 2022 | Netherlands | Series B | 4062 | [+5] |
Acquired companies in Bluebird Ventures' Portfolio
2 companies from Bluebird Ventures' portfolio have been acquired. The most recent acquisition was Foresight Diagnostics in Dec 2025 by Natera for $*****.Here are Bluebird Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 11, 2025 | Jun 02, 2021 | Series A | 5262 | |
Mar 02, 2020 | - | - | 7151 |
Co-investors of Bluebird Ventures
Over the past 7 years, 45 investors have co-invested in Bluebird Ventures's portfolio companies. This includes funds and angels.
- Invested before Bluebird Ventures: QVT Family Office, Dexcel and 12 others have invested in rounds before Bluebird Ventures. There is 1 company where QVT Family Office has invested before Bluebird Ventures and 1 company where Dexcel has invested before Bluebird Ventures.
- Top Co-investors of Bluebird Ventures: 16 investors entered a company along with Bluebird Ventures. These include investors like Civilization Ventures (1 company).
- Invested after Bluebird Ventures: A total of 15 investors have invested in Bluebird Ventures's portfolio after their investments. Top Investors include Foresite Capital (1 company), Agent Capital (1 company) and Stanford University (1 company).
Recent News related to Bluebird Ventures
•
Milvus Advanced Secures Seed Funding to Scale Nanoalloy TechPR Newswire•Oct 21, 2025•Hoxton Ventures, Milvus Advanced, Bluebirds, MD One Ventures and 7 others
•
Leyden Labs Raises $70M to Advance its Intranasal Antibody Programs to Protect against Influenza and other VirusesBusiness Wire•Jan 09, 2025•Leyden Labs, Clavystbio, Polaris Partners, Qiming Venture Partners and 13 others
•
Foresight Diagnostics completes nearly $74M Series B funding roundDailycamera•Aug 02, 2024•Foresight Diagnostics, Foresite Capital, Civilization Ventures, Bluebird Ventures and 3 others
•
Bio-techne Announces Strategic Investment In Spear BioPR Newswire•Jul 29, 2024•Bio-Techne, Spear Bio, CDH, Yonjin Capital and 7 others
•
Procyrion Closes $57.7 Million in Series E FinancingMedical Product Outsourcing•Apr 11, 2024•Procyrion, Fannin Innovation Studio, Bluebird Ventures
•
Medical device company Procyrion Closes $57.7 Million Series E Financing RoundSilicon Valley Journals•Feb 06, 2024•Procyrion, Fannin Innovation Studio, Bluebird Ventures
•
Procyrion raises $57M to complete development of its percutaneous heart failure pumpFierce Biotech•Feb 05, 2024•Procyrion, Fannin Innovation Studio, Palo Alto Networks, Bluebird Ventures
•
Foresight Diagnostics Closes $58.8M Series B Round360Dx•Apr 27, 2023•Foresight Diagnostics, Agent Capital, Pear VC, Bluebird Ventures and 2 others
•
Kriya Announces $270 Million Series C Financing to Advance Fully Integrated Gene Therapy EngineBusiness Wire•May 16, 2022•Kriya Therapeutics, Transhuman Capital, QVT Family Office, Narya and 7 others
•
Firm Advises on Leyden Labs’ $140M Fundraising RoundBrown Rudnick•Jan 27, 2022•Brown Rudnick, Byers Capital, Leyden Labs, Casdin Capital and 6 others
